Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VENICE clinical trial evaluating the investigational agent Zaltrap (aflibercept) in the first-line treatment of men with castrate resistant prostate cancer will continue to completion as planned. They have not been asked to make any modifications due to efficacy or to safety concerns. This decision is based on [...]
Yesterday, Amgen announced that it had submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand its license for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, XGEVA would be the first therapy licensed to prevent or [...]
According to findings from a long term study, men with prostate cancer (PCa) who are treated with degarelix (a newly approved gonadotropin-releasing hormone receptor (GnRH) blocker) have a lower risk of PSA failure or death compared with those treated with leuprolide. […]
Data from the recent ASCO conference on a phase II study of cabozantinib (XL184) in patients with advanced solid tumors, including prostate cancer, demonstrates that the investigational treatment has activity in both bone and soft tissue. This study evaluated the efficacy and safety of cabozantinib compared to placebo in 9 different solid tumor types including [...]
There is good reason for guarded optimism among men with advanced prostate cancer. Over the last 2 years we have seen some significant movement with the development of new drugs and treatments for men with advanced prostate cancer. All of these drugs have demonstrated a survival advantage in their clinical trials. Each of the agents [...]